Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / COM
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
26.6M
-
Shares change
-
+22.3M
-
Total reported value, excl. options
-
$257M
-
Value change
-
+$216M
-
Number of buys
-
63
-
Number of sells
-
-1
-
Price
-
$9.68
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q1 2017
69 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q1 2017.
AVADEL PHARMACEUTICALS - COM (AVDL) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.6M shares
.
Largest 10 shareholders include Broadfin Capital, LLC (4.39M shares), DEERFIELD MANAGEMENT CO (4.07M shares), JANUS CAPITAL MANAGEMENT LLC (2.17M shares), Bank of New York Mellon Corp (1.78M shares), ACADIAN ASSET MANAGEMENT LLC (1.52M shares), PERCEPTIVE ADVISORS LLC (1.41M shares), DEUTSCHE BANK AG\ (1.18M shares), J. Goldman & Co LP (997K shares), BROWN CAPITAL MANAGEMENT LLC (964K shares), and ARMISTICE CAPITAL, LLC (956K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.